UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Quote | UCB S.A. ADR (OTCMKTS:UCBJY)
Last: | $66.575 |
---|---|
Change Percent: | -1.08% |
Open: | $66.23 |
Close: | $67.30 |
High: | $66.63 |
Low: | $66.23 |
Volume: | 35,114 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | UCB S.A. ADR (OTCMKTS:UCBJY)
2024-04-25 12:40:30 ET More on UCB SA UCB SA (UCBJF) Full Year 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on UCB SA Historical earnings data for UCB SA Dividend scorecard for UCB SA Financial information for UCB SA Rea...
2024-04-24 10:00:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio meaningfully beat the benchmark MSCI EAFE Index, as well as the seconda...
Message Board Posts | UCB S.A. ADR (OTCMKTS:UCBJY)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $UCBJY News Article - Epilepsia Publishes Interim Results of Open-Label Extension Study | whytestocks | investorshangout | 11/23/2022 5:45:53 PM |
Stock_Tracker: Latest Ucb ADR (UCBJY) Headlines UCB's Kremers Urban Pharmaceuticals Inc. receives FD | Stock_Tracker | investorshangout | 03/12/2014 2:50:14 AM |
chartguy89: UCBJY 40.69 Stock Charts $UCBJY 1 Month Chart | chartguy89 | investorshangout | 03/10/2014 2:38:13 PM |
chartguy89: UCBJY Stock Charts Last: +1.00 Sunday, March 2, 2014 at 4:19:38 AM $UCBJY 1 Mont | chartguy89 | investorshangout | 03/02/2014 9:19:49 AM |
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting PR Newswire Diverse and patient-focused data set comprises 17 abstracts including one oral presentation Features new data analyse...
UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa PR Newswire Campaign offers resources and information about hidradenitis suppurativa (HS) and amplifies diverse patient voices and stories to reach p...
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations PR Newswire Application in moderate-to-severe hidradenitis suppurativa based on results from two...